Vivo Capital — 2024 Investments
1 investments dated 2024 · listed companies and verified rows first · show all
Attralusattralus.comin𝕏Feb 2024 · $56M
Attralus develops pan-amyloid removal (PAR) therapeutics — biologics and imaging agents designed to bind and remove toxic amyloid — to treat patients with systemic amyloidosis across all disease types and stages.
BiotechHealthtechSouth San Francisco, US
Jonathan Wall(Executive Officer)Spencer Guthrie(Executive Officer)Mark Timney(Executive Officer, Director)Benson Fong(Executive Officer)Rahul Kakkar(Director)Greg Bell(Executive Officer)
Co-investorsAlpha Wave GlobalBioBritvenBio PartnersvenBio Global Strategic
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.